439 related articles for article (PubMed ID: 19789368)
41. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Kawasaki T; Ohnishi M; Suemoto Y; Kirkner GJ; Liu Z; Yamamoto H; Loda M; Fuchs CS; Ogino S
Mod Pathol; 2008 Feb; 21(2):150-8. PubMed ID: 18084250
[TBL] [Abstract][Full Text] [Related]
42. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
[TBL] [Abstract][Full Text] [Related]
43. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A
Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933
[TBL] [Abstract][Full Text] [Related]
44. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.
Guedes JG; Veiga I; Rocha P; Pinto P; Pinto C; Pinheiro M; Peixoto A; Fragoso M; Raimundo A; Ferreira P; Machado M; Sousa N; Lopes P; Araújo A; Macedo J; Alves F; Coutinho C; Henrique R; Santos LL; Teixeira MR
BMC Cancer; 2013 Apr; 13():169. PubMed ID: 23548132
[TBL] [Abstract][Full Text] [Related]
45. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer.
Lochhead P; Imamura Y; Morikawa T; Kuchiba A; Yamauchi M; Liao X; Qian ZR; Nishihara R; Wu K; Meyerhardt JA; Fuchs CS; Ogino S
Eur J Cancer; 2012 Dec; 48(18):3405-13. PubMed ID: 22840368
[TBL] [Abstract][Full Text] [Related]
46. JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype.
Nosho K; Shima K; Kure S; Irahara N; Baba Y; Chen L; Kirkner GJ; Fuchs CS; Ogino S
Neoplasia; 2009 Jan; 11(1):87-95. PubMed ID: 19107235
[TBL] [Abstract][Full Text] [Related]
47. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Ogino S; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS
Int J Cancer; 2008 Jun; 122(12):2767-73. PubMed ID: 18366060
[TBL] [Abstract][Full Text] [Related]
48. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
49. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
Baba Y; Nosho K; Shima K; Freed E; Irahara N; Philips J; Meyerhardt JA; Hornick JL; Shivdasani RA; Fuchs CS; Ogino S
Clin Cancer Res; 2009 Jul; 15(14):4665-73. PubMed ID: 19584150
[TBL] [Abstract][Full Text] [Related]
50. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.
Domingo E; Ramamoorthy R; Oukrif D; Rosmarin D; Presz M; Wang H; Pulker H; Lockstone H; Hveem T; Cranston T; Danielsen H; Novelli M; Davidson B; Xu ZZ; Molloy P; Johnstone E; Holmes C; Midgley R; Kerr D; Sieber O; Tomlinson I
J Pathol; 2013 Feb; 229(3):441-8. PubMed ID: 23165447
[TBL] [Abstract][Full Text] [Related]
51. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
52. IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53.
Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS; Ogino S
Neoplasia; 2007 Dec; 9(12):1091-8. PubMed ID: 18084616
[TBL] [Abstract][Full Text] [Related]
53. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
[TBL] [Abstract][Full Text] [Related]
54. Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans.
Kumar K; Brim H; Giardiello F; Smoot DT; Nouraie M; Lee EL; Ashktorab H
Clin Cancer Res; 2009 Feb; 15(4):1155-61. PubMed ID: 19190129
[TBL] [Abstract][Full Text] [Related]
55. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma.
Kakar S; Deng G; Smyrk TC; Cun L; Sahai V; Kim YS
Mod Pathol; 2012 Jul; 25(7):1040-7. PubMed ID: 22522845
[TBL] [Abstract][Full Text] [Related]
56. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
[TBL] [Abstract][Full Text] [Related]
57. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
Li HT; Lu YY; An YX; Wang X; Zhao QC
Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
[TBL] [Abstract][Full Text] [Related]
58. CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis.
Fu T; Pappou EP; Guzzetta AA; Jeschke J; Kwak R; Dave P; Hooker CM; Morgan R; Baylin SB; Iacobuzio-Donahue CA; Wolfgang CL; Ahuja N
Clin Cancer Res; 2012 Sep; 18(17):4743-52. PubMed ID: 22825585
[TBL] [Abstract][Full Text] [Related]
59. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
60. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers.
Baba Y; Nosho K; Shima K; Hayashi M; Meyerhardt JA; Chan AT; Giovannucci E; Fuchs CS; Ogino S
Cancer; 2011 Apr; 117(7):1399-408. PubMed ID: 21425139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
